[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-455707-105":59,"doc-detail-455707-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-markers-of-antimalarial-drug-resistance-in-plasmodium-falciparum-from-kumasi-ghana-2023","Molecular Markers of Antimalarial Drug Resistance in Plasmodium falciparum From Kumasi, Ghana, 2023","","Artemisinin partial resistance has emerged in East Africa and threatens the effectiveness of artemisinin-based combination therapy (ACT). Molecular markers can provide early warnings for specific drug-resistance development before clinical treatment failure becomes widespread. This study updates resistance-marker information for Plasmodium falciparum from Kumasi, Ghana, using 2023 patient isolates and assessing genotyped mutations and selected day-3 parasitemia after artemether-lumefantrine treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-markers-of-antimalarial-drug-resistance-in-plasmodium-falciparum-from-kumasi-ghana-2023/455707/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-markers-of-antimalarial-drug-resistance-in-plasmodium-falciparum-from-kumasi-ghana-2023/455707.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-07","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study in Kumasi, Ghana (2023)?","Question",{"text":112,"@type":113},"To update information on molecular resistance markers in Plasmodium falciparum and assess their relevance to artemisinin-based combination treatment effectiveness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which genetic markers and mutations were genotyped for antimalarial resistance?",{"text":117,"@type":113},"Mutations were genotyped in pfk13 (including P76S as pfcoronin and specific pfk13 mutations), pfcoronin (P76S), pfmdr1 (N86Y, Y184F, Y1246D), and pfaat1 (S258L).",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings about resistance marker prevalence and associations?",{"text":121,"@type":113},"Non-synonymous pfk13 mutations were found in 2.2% of isolates, pfcoronin P76S appeared in 29.7% and was linked with lower parasite density, pfmdr1 patterns suggested impaired lumefantrine sensitivity, and resistance markers were not associated with each other or with day-3 parasite positivity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},455707,1790924234,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?_k=1776742907772140068","Tropical Medicine & International Health  \n SHORT COMMUNICATION  OPEN ACCESS   \nMolecular Markers of Antimalarial Drug Resistance in Plasmodium falciparum From Kumasi, Ghana, 2023  \nAlbert Dennis Kegya1  | Elizabeth Oppong2 | Eric Darko2 | Kwame Ayisi Boateng2  | Richard Odame Phillips1,2  | Melina Heinemann3,4  | Michael Ramharter3,5  | Clement Igiraneza6 | Jules Minega Ndoli6 | Frank P. Mockenhaupt7  | Welmoed van Loon7   \n1Kumasi Centre for Collaborative Research in Tropical Medicine, Kumasi, Ghana | 2University Hospital, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana | 3Center for Tropical Medicine, Bernhard-Nocht-Institute for Tropical Medicine & I. Dep. of Medicine University Medical Centre Hamburg-Eppendorf, Hamburg, Germany | 4Department of Internal Medicine, University Hospital and University of Zurich, Zurich, Switzerland | 5German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany | 6University Teaching Hospital of Butare, University of Rwanda, Butare, Rwanda | 7Institute of International Health, Charité Center for Global Health, Charité – Universitaetsmedizin Berlin, Berlin, Germany  \nCorrespondence: Welmoed van Loon ([welmoed.van-loon@charite.de](welmoed.van-loon@charite.de))  \nReceived: 29 April 2025 | Revised: 14 September 2025 | Accepted: 1 October 2025  \nFunding: This study was funded by the Hospital Partnerships programme of the Federal Ministry for Economic Cooperation and Development and the Else Kröner-Fresenius-Stiftung (grant 21Ac10060) .  \nKeywords: artemisinin | Ghana | malaria | pfaat1 | pfcoronin | pfk13 | pfmdr1 | resistance  \nABSTRACT  \nObjectives: Artemisinin partial resistance has emerged in East Africa and is feared to spread across the continent, potentially compromising artemisinin-based combination treatment. Molecular markers can serve as early warning signals for the development of specific drug resistance. We aimed at updating information on relevant resistance markers among Plasmodium falciparum from Kumasi, Ghana, collected in 2023.  \nMethods: P. falciparum isolates were obtained from 200 patients with falciparum malaria. Mutations in pfk13 (propeller domain), pfcoronin (P76S), pfmdr1 (N86Y, Y184F, Y1246D) and pfaat1 (S258L) were genotyped. A subset of patients was microscopically examined for the presence of asexual malaria parasites on day-3 of treatment with artemether-lumefantrine.  \nResults: 2.2% of isolates exhibited non-synonymous pfk13 mutations including the candidate artemisinin partial resistance marker P527H in addition to S522C, C532S and I590V. Pfcoronin P76S, previously associated with artemether-lumefantrine failure in malaria imported from Africa, was present in 29.7% and associated with a lower parasite density. The predominance of thepfmdr1 pattern N86-184F-D1246 (NFD) suggested impaired sensitivity to lumefantrine. Pfaat1 S258L was common at 64.7% . The resistance markers were not associated with each other, and they were not linked with day-3 parasite positivity.  \nConclusions: While the efficacy of artemisinin-based combination treatment in Ghana is still high, isolated critical pfk13 polymorphisms were identified as well as a considerable prevalence of a potentially relevant pfcoronin marker, against a background of pfmdr1 signals for impaired lumefantrine sensitivity. Continuous molecular monitoring is necessary to detect threats to artemisinin-based combination treatment efficacy at an early stage.  \n\n| Sustainable Development Goal: Good Health and Wellbeing |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2025 The Author(s) . Tropical Medicine & International Health published by John Wiley & Sons Ltd. |\n\nTropical Medicine & International Health, 2026; 31:43–48 43  \n[https://doi.org/10.1111/tmi.70048](https://doi.org/10.1111/tmi.70048)  \n","cbCaivtSMTZCkZxc","https://ap.wps.com/l/cbCaivtSMTZCkZxc","pdf",226805,"English","# Background\n# Molecular markers and resistance mechanisms\n# Objectives\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the main objective of the study in Kumasi, Ghana (2023)?\",\"answer\":\"To update information on molecular resistance markers in Plasmodium falciparum and assess their relevance to artemisinin-based combination treatment effectiveness.\"},{\"question\":\"Which genetic markers and mutations were genotyped for antimalarial resistance?\",\"answer\":\"Mutations were genotyped in pfk13 (including P76S as pfcoronin and specific pfk13 mutations), pfcoronin (P76S), pfmdr1 (N86Y, Y184F, Y1246D), and pfaat1 (S258L).\"},{\"question\":\"What were the key findings about resistance marker prevalence and associations?\",\"answer\":\"Non-synonymous pfk13 mutations were found in 2.2% of isolates, pfcoronin P76S appeared in 29.7% and was linked with lower parasite density, pfmdr1 patterns suggested impaired lumefantrine sensitivity, and resistance markers were not associated with each other or with day-3 parasite positivity.\"}]","Molecular Markers of Antimalarial Drug Resistance in Plasmodium falciparum From Kumasi, Ghana, 2023 | PDF",1790743937,15]